SRA's number for the day: 4
This article was originally published in SRA
Executive Summary
The European Medicines Agency is being reorganized and will soon have four new divisions focussing on: supporting the R&D phase in drug companies; medicines evaluation and lifecycle management; procedure management and business data; and inspections and pharmacovigilance1.
You may also be interested in...
Global Inspection Body To Check Value Of Exchanging Data On ‘Borderline Compliance’ Cases
The 2021 work plan of PIC/S, the international group of pharmaceutical inspectorates, includes renewed efforts to carry out projects that could not be completed due to the coronavirus pandemic.
EU Nitrosamines Oversight Group Sets Priorities
After agreeing on an EU-wide harmonized approach to deal with nitrosamine contamination in medicines, a recently formed regulatory oversight group has identified several topics requiring further scientific discussion.
EMA Reviews GSK/Vir’s COVID-19 Antibody To Support Early Use By Member States
After preliminary discussions with its pandemic task force, the European Medicines Agency has begun reviewing GSK/Vir Biotechnology’s promising COVID-19 treatment to help EU national competent authorities make evidence-based decisions on its possible early use.